$10,316.29 ownership Payment -- AstraZeneca to Dr. Rebecca Adams
Cardiologist Receives Over $10,000 Ownership Interest from AstraZeneca
This page provides a detailed analysis of a $10,316.29 ownership payment from AstraZeneca to Dr. Rebecca Adams. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $10,316.29 |
| Payment Type | ownership |
| Payment Nature | Ownership or Investment Interest |
| Pharmaceutical Company | AstraZeneca |
| Physician | Dr. Rebecca Adams |
| NPI Number | 1699148064 |
| Physician Specialty | Cardiology |
| Location | City, MN |
| Date of Payment | 2025-04-04 |
| Related Drug/Device | Stelara |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
AstraZeneca made a $10.3K ownership payment to Rebecca Adams, a Cardiology specialist in City, MN. The payment was associated with Stelara. This record details a significant ownership interest payment of $10,316.29 to Dr. Rebecca Adams, a Cardiologist. The payment is associated with AstraZeneca and relates to an ownership or investment interest, not directly tied to a specific drug or device like Stelara in this entry. The payment date is in the future (April 4, 2025), suggesting this might be a pre-scheduled or reported future transaction.
Patient Guidance: What This Payment Means for You
This information reflects a financial relationship between a pharmaceutical company and a healthcare provider, which may influence treatment options. Discuss any concerns about your doctor's financial ties with them directly. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Ownership interests are common in the pharmaceutical industry, but the amount and nature of this specific investment for a Cardiologist should be considered in the context of typical financial relationships within the specialty.
Regulatory Context: Sunshine Act Requirements
This payment is reported under the Physician Payments Sunshine Act, part of the Affordable Care Act, requiring disclosure of financial relationships between drug and device manufacturers and physicians.
Related Topics
This payment is related to the following healthcare transparency topics:
- ownership-interest
- astrazeneca
- cardiology
- rebecca-adams
- pharmaceutical-investment
- cms-open-payments
Understanding ownership Payments
Ownership and investment interest payments represent dividends, returns, or other financial benefits from physician ownership stakes in pharmaceutical or medical device companies. These relationships represent the most direct form of financial interest and are subject to the strictest reporting requirements under the Sunshine Act.
Frequently Asked Questions About This Payment
What was this $10.3K payment for?
This was a ownership payment of $10.3K from AstraZeneca to Rebecca Adams, categorized as "Ownership or Investment Interest". It was associated with Stelara. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Rebecca Adams accept pharmaceutical money?
Yes, Rebecca Adams received this $10.3K payment from AstraZeneca. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Rebecca Adams's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this ownership payment?
A ownership payment of $10.3K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Cardiology?
To compare this payment against Cardiology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Cardiology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Rebecca Adams's relationship with AstraZeneca?
The payment type is 'ownership', indicating a financial stake rather than a fee for services. This $10.3K ownership payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Cardiology?
While Stelara is mentioned, the payment nature is 'Ownership or Investment Interest', suggesting the investment may be broader than a single product.
What should patients do after learning about this payment?
This information reflects a financial relationship between a pharmaceutical company and a healthcare provider, which may influence treatment options. Discuss any concerns about your doctor's financial ties with them directly.
What else should I know about this ownership payment?
The payment is scheduled for a future date, which is unusual for standard reporting of completed transactions.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.